Compare Stocks

→ Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APHB Ampliphi Biosciences	$2.51 -6.0%	$0.00	$0.15 ▼ $1.37	$84.01M	N/A	842,200 shs	5,098 shs
CRMD CorMedix	$5.45 +3.2%	$4.14	$2.57 ▼ $7.00	$298.73M	1.86	551,880 shs	572,756 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	+3.22%	+0.74%	+39.03%	+70.31%	+11.91%

Exposed: 10 CENT Crypto to Explode April 20th? (Ad)

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Click For My #1 FREE Crypto for 2024

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	1.5081 of 5 stars	3.5	0.0	0.0	0.0	3.1	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A
CRMD CorMedix	3.00	Buy	$13.00	138.53% Upside

Current Analyst Ratings

Latest APHB, ARIX, and CRMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2024	CRMD CorMedix	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
4/9/2024	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/13/2024	CRMD CorMedix	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
1/31/2024	CRMD CorMedix	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	$60K	4,978.76	N/A	N/A	$1.28 per share	4.26

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APHB Ampliphi Biosciences	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	-$46.34M	-$0.92	N/A	N/A	N/A	N/A	-72.31%	-63.97%	5/20/2024 (Estimated)

Latest APHB, ARIX, and CRMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/12/2024	Q4 2023	CRMD CorMedix	-$0.21	-$0.26	-$0.05	-$0.26	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APHB Ampliphi Biosciences	N/A	N/A	N/A
CRMD CorMedix	N/A	6.97	6.78

Ownership

Institutional Ownership

Company	Institutional Ownership
APHB Ampliphi Biosciences	N/A
CRMD CorMedix	34.18%

Insider Ownership

Company	Insider Ownership
APHB Ampliphi Biosciences	N/A
CRMD CorMedix	3.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APHB Ampliphi Biosciences	30	33.47 million	N/A	Not Optionable
CRMD CorMedix	82	54.81 million	52.29 million	Optionable

APHB, CRMD, and ARIX Headlines

Source	Headline
	CorMedix product 'DefenCath' gains CMS transitional payment status investing.com - April 20 at 9:09 PM
	CorMedix, Inc.: CorMedix Inc. Announces CMS Grants TDAPA to DefenCath finanznachrichten.de - April 20 at 6:24 PM
	CorMedix Shares Rise 6% After DefenCath Meets Payment Criteria marketwatch.com - April 19 at 12:25 PM
	CorMedix Inc. Announces CMS Grants TDAPA to DefenCath globenewswire.com - April 19 at 8:30 AM
	CorMedix Inc. (NASDAQ:CRMD) Short Interest Up 6.2% in March americanbankingnews.com - April 18 at 2:38 AM
	Short Interest in CorMedix Inc. (NASDAQ:CRMD) Increases By 6.2% marketbeat.com - April 16 at 12:23 PM
	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential investorplace.com - April 15 at 12:54 PM
	CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin) globenewswire.com - April 15 at 8:30 AM
	CRMD Apr 2024 7.000 call finance.yahoo.com - April 15 at 12:28 AM
	CRMD Apr 2024 8.000 put finance.yahoo.com - April 15 at 12:28 AM
	Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know zacks.com - April 11 at 10:55 AM
	CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference finance.yahoo.com - April 11 at 8:44 AM
	CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference globenewswire.com - April 11 at 8:30 AM
	CorMedix (NASDAQ:CRMD) Receives Market Outperform Rating from JMP Securities marketbeat.com - April 9 at 8:49 AM
	Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD) markets.businessinsider.com - April 9 at 7:36 AM
	CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC globenewswire.com - April 8 at 8:30 AM
	Breakeven On The Horizon For CorMedix Inc. (NASDAQ:CRMD) finance.yahoo.com - April 2 at 12:24 PM
	CorMedix Inc. to Present at the Needham Annual Healthcare Conference finance.yahoo.com - March 27 at 9:34 AM
	CRMD Apr 2024 6.000 put finance.yahoo.com - March 16 at 9:19 AM
	CRMD Apr 2024 3.000 put finance.yahoo.com - March 16 at 8:46 AM
	CRMD Apr 2024 3.000 call finance.yahoo.com - March 16 at 8:16 AM
	CorMedix Inc. (NASDAQ:CRMD) CEO Joseph Todisco Purchases 13,561 Shares insidertrades.com - March 15 at 11:42 AM
	Truist Financial Reaffirms Their Buy Rating on Cormedix (CRMD) markets.businessinsider.com - March 13 at 8:41 PM
	Analysts Offer Insights on Healthcare Companies: Cencora (COR), Cormedix (CRMD) and NeueHealth Inc (NEUE) markets.businessinsider.com - March 13 at 1:26 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Ampliphi Biosciences

NYSEAMERICAN:APHB

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

CorMedix

NASDAQ:CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial